QIAamp® DSP Virus Spin Kit

The QIAamp DSP Virus Spin Kit is designed for manual or automated purification of viral nucleic acids from human plasma and serum. The kit is designed to provide rapid and reliable viral DNA and RNA purification while minimizing cross-contamination risks.

Kit performance is not guaranteed for each virus species and must be validated by the user. It is the user's responsibility to validate system performance for any procedures used in their laboratory that are not covered by the QIAGEN® performance evaluation studies.

Performance characteristics

The performance of the QIAcube for the QIAamp DSP Virus Spin Kit was compared using hepatitis C virus (HCV) RNA as an example virus. The tests were performed with a dilution of quantified virus panels made in HCV-negative human plasma and serum (n=15).

HCV RNA was detected using an in-house RT-PCR assay (Figure 1). Viral nucleic acids were purified from 200 or 400 µl samples with an elution volume of 60 µl.



Figure 1. Performance comparison of the QIAamp DSP Virus Spin Kit. The performance of the QIAamp DSP Virus Spin Kit in combination with different protocols was compared by analysis of serum and plasma samples. The QIAcube protocols used were: QIAamp DSP Virus Spin — Large Plasma Samples — Standard (400 µl); QIAamp DSP Virus Spin — Large Plasma Samples — Manual Lysis (400 µl); QIAamp DSP Virus Spin — Standard (200 µl, plasma or serum samples); and QIAamp DSP Virus Spin — Manual Lysis (200 µl, plasma or serum samples). Viral RNA was detected using viral dilution series and an in-house RT-PCR assay for HCV RNA.

February 2012

Linear range

Hepatitis C virus (HCV) RNA was extracted using the QIAamp DSP Virus Spin Kit with one manual and two automated QIAcube protocols: QIAamp DSP Virus Spin (200 µl); automated QIAamp DSP Virus Spin — Large Plasma Samples — Standard (400 µl); and automated QIAamp DSP Virus Spin — Standard (200 µl). Performance of the QIAamp DSP Virus Spin Kit was compared to the QIAamp DSP Virus Kit using the manual QIAamp DSP Virus protocol (500 µl) together with the QIAvac 24 Plus system. The tests were performed with dilutions of quantified virus panels made in HCV-negative human plasma. Dilution series with 5 different virus titers were tested, with 12 replicates each. The linear range of the QIAamp DSP Virus Spin Kit procedure was determined for HCV using an in-house RT-PCR assay (Figure 2). Viral nucleic acids were purified from sample volumes of 200–500 µl, with a 60 µl elution volume.



Figure 2. The linear range of the QIAamp DSP Virus Spin Kit. The linear range of yields using the QIAamp DSP Virus Spin Kit (cat. no. 61704) with 1 manual and 2 different automated protocols, compared to the manual QIAamp DSP Virus Kit (cat. no. 60704) procedure using the QIAvac 24 Plus. The linear range of the protocols was determined using viral dilution series and an in-house RT-PCR assay for HCV RNA.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit handbook or user manual. QIAGEN kit handbooks and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services or your local distributor.

www.qiagen.com

Australia ■ 1-800-243-800
Austria ■ 0800/281010
Belgium ■ 0800-79612
China ■ 021-51345678
Denmark ■ 80-885945
Finland ■ 0800-914416
France ■ 01-60-920-930
Germany ■ 02103-29-12000
Hong Kong ■ 800 933 965
Ireland ■ 1800 555 049
Italy ■ 800 787980
Japan ■ 03-5547-0811
Korea (South) ■ 1544 7145
Luxembourg ■ 8002 2076
The Netherlands ■ 0800 0229592
Norway ■ 800-18859
Singapore ■ 65-67775366
Spain ■ 91-630-7050
Sweden ■ 020-790282
Switzerland ■ 055-254-22-11
UK ■ 01293-422-911

Sample & Assay Technologies